Executive Summary
Key Events by Therapeutic Class
Directly TNF-α-Targeted Therapies
- XPro1595 (INmune Bio): FDA End-of-Phase 2 meeting confirmed regulatory alignment on an integrated Phase 2b/3 registration pathway in early Alzheimer's disease, with CDR-SB as the sole primary endpoint, inflammation-based biomarker enrichment accepted, and approximately 1,000-participant program design cleared with no objection.[1]
- NAV-240 (Navigator Medicines): FDA IND clearance received for a Phase 2a trial of the OX40L/TNF-α bispecific antibody in moderate-to-severe hidradenitis suppurativa, with dosing initiated Q1 2026.[11]
- NAV-242 (Navigator Medicines): Australian HREC approval received for the Phase 1 first-in-human program of the next-generation half-life-extended OX40L/TNF-α bispecific antibody, with SAD results expected Q4 2026.[11]
- SOR102 (Sorriso Pharma): Phase 1 first-in-human data published for the oral bispecific anti-TNF/IL-23 antibody, demonstrating 43–56% clinical response rates at day 42 in UC patients versus 17% for placebo.[7]
- Adalimumab (AbbVie): The ADVISE trial demonstrated superiority over conventional immunosuppression for corticosteroid sparing at 6 months (69% vs. 54%; p=0.029) and corticosteroid discontinuation at 12 months (55% vs. 40%; p=0.028) in non-infectious uveitis.[2]
- Infliximab / Adalimumab (J&J / AbbVie): Post-hoc analysis of 300 UC patients from HIBISCUS I/II and GARDENIA found anti-TNF therapy drives a proximal-to-distal colonic healing pattern, and combined MES + PRO2 endpoint outperformed PRO2 alone (28.6% vs. 13.3%; p=0.006).[8]
- Certolizumab Pegol (UCB): Post-hoc analysis of 930 RA patients from the REALISTIC trial confirmed that high rheumatoid factor levels (≥180 kU/L) do not diminish CZP efficacy, and that prior TNFi failure does not predict reduced CZP response.[3]
- Infliximab + Azathioprine vs. Rifaximin + Azathioprine (J&J / Generic): Prospective cohort of 130 IBD patients demonstrated IFX+AZA is superior for acute TNF-α-driven inflammation control during induction, while RIF+AZA offers superior mucosal healing and oxidative balance, supporting a two-phase induction–maintenance strategy.[10]
**TNF-
